An observational study in Aortic Stenosis, Chronic Coronary Syndrome and Calcific Aortic Valve Disease, sponsored by Azienda Ospedaliera "Sant'Andrea". Recruiting at 5 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.
Sponsored by Azienda Ospedaliera "Sant'Andrea" · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 118 studies in Aortic Valve Stenosis with a site in Italy — 39 open to participants now, 54 under way, 1 of them phase 3. Aortic Valve Stenosis · Italy.
Among the 118 studies in Aortic Valve Stenosis with a site in Italy, this one is the 50th largest by planned enrollment of the 71 observational ones that give a count, is one of 4 that started in 2026, is one of 71 observational ones, reaches primary completion later than 31 of the 53 other live ones, and was the 116th registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →39 of the 118 studies in Aortic Valve Stenosis with a site in Italy are open now. Recruiting first, the newest first:
University Hospital of Ferrara · Sites in Italy
Ages 75+
University Hospital of Ferrara · Sites in Italy
IRCCS Policlinico S. Donato · Sites in Italy
Ages 18+
IRCCS Policlinico S. Donato · Sites in Italy
Ages 18+
Ceric Sàrl · Sites in Italy, Austria, Estonia and 11 more countries
Ages 65–75
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
118 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is above the median of 200 across 437 observational studies indexed under Aortic Valve Stenosis.
Median enrollment 300 across the 47 interventional studies, 500 across the 71 observational. Of the 53 that completed or were terminated, 15 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 118 have an industry lead sponsor. The 10 most frequent:
Azienda Ospedaliera "Sant'Andrea" is the lead sponsor of 7 studies on the registry; 3 are open to participants now.
Azienda Ospedaliera "Sant'Andrea" has 1 study filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
9 of the studies in Aortic Valve Stenosis with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07620925Azienda Ospedaliera "Sant'Andrea"Derivation and Validation of the Aortic Valve Echocardiographic Calcium Score to Confirm Severe Aortic Stenosis: the Echo-AVCS Study | 2026-12-31 |
| NCT06859255IRCCS Policlinico S. DonatoIn-vitro Benchmarking of Currently Available Heart Valve Prostheses for Surgical and Percutaneous Treatment of Aortic Stenosis With Small Annulus, Followed by In-vivo Validation | 2027-02-07 |
| NCT05779787Niguarda HospitalCOronary Re-engageMent aFter randOm NavitoR alignmenT (COMFORT STUDY) | 2027-02-15 |
| NCT05751577Azienda Usl di BolognaTRanscatheter Aortic-Valve Implantation With or Without On-site Cardiac Surgery: the TRACS Trial | 2027-03-31 |
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
Add all 9 to your calendar (.ics) → With an account.
Among the 118 studies in Aortic Valve Stenosis with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Echo-AVCS Study is an investigator-initiated, prospective, multicenter observational study designed to derive and validate an artificial intelligence (AI)-based echocardiographic aortic valve calcium score (Echo-AVCS) for confirming severe aortic stenosis (AS). Transthoracic echocardiography (TTE) is the standard imaging modality for assessing AS severity; however, discrepancies between valve area and transvalvular gradient measurements may complicate diagnosis, particularly in low-flow or discordant AS presentations. Cardiac computed tomography (CT)-derived aortic valve calcium scoring is currently used to resolve diagnostic uncertainty, but it involves additional cost and radiation exposure. This study will enroll consecutive adult patients undergoing clinically indicated TTE and cardiac CT with calcium scoring performed within 3 months. Standardized echocardiographic images will be centrally analyzed using dedicated AI-based image segmentation and machine learning methods to quantify aortic valve calcification directly from TTE images. CT-derived aortic valve calcium score will serve as the reference standard. The primary objective is to derive and validate the Echo-AVCS score for identifying severe AS. Secondary objectives include determination of sex-specific diagnostic thresholds, correlation with CT calcium volume, association with symptoms and NYHA class, and evaluation of prognostic associations with aortic valve replacement, heart failure hospitalization, cardiovascular events, and mortality at 1-year follow-up.
The Echo-CA score Study is an investigator-initiated, prospective, multicenter study of consecutive patients undergoing clinically indicated standard transthoracic echocardiography and cardiac CT with available calcium score performed within 3 months. The study population is expected to include approximately 50% patients with severe AS and 50% without severe AS, in order to ensure a balanced case-control distribution and optimize the precision of diagnostic performance estimates. All patients will be managed according to current standards of care. Clinical evaluation will include systematic collection of cardiovascular risk factors, comorbidities, medical therapy, and detailed symptom assessment (angina, syncope, dyspnea), as well as NYHA functional class. Each participant will undergo: i) comprehensive transthoracic echocardiography (TTE) performed according to current ESC Guideline; ii) cardiac CT with aortic valve calcium quantification, performed according to contemporary acquisiti
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Consecutive patients undergoing clinically indicated standard transthoracic echocardiography and cardiac CT with available calcium score performed within 3 months
Diagnostic Test: Echocardiography and Cardiac CT
This is a non-interventional, observational study in which all patients will undergo clinically indicated standard-of-care transthoracic echocardiography (TTE) and cardiac computed tomography (CT) with aortic valve calcium scoring. No investigational drug, device, or additional invasive procedure will be administered as part of the study. Echocardiographic images acquired during routine clinical practice will be anonymized and centrally analyzed using dedicated artificial intelligence-based software to derive and validate the echocardiographic aortic valve calcium score. Patient management, follow-up, and therapeutic decisions, including referral for aortic valve replacement, will remain entirely at the discretion of the treating physicians according to current clinical guidelines and standard practice.
Derivation of Echo-AVCS
To derive an echocardiographic aortic valve calcium score (Echo-AVCS) for confirming severe aortic stenosis (AS), using CT-derived aortic valve calcium as the reference standard.
Time frame: 6 months
Validation of Echo-AVCS
To validate an echocardiographic aortic valve calcium score (Echo-AVCS) for confirming severe aortic stenosis (AS), using CT-derived aortic valve calcium as the reference standard.
Time frame: 6 months
Sex-specific thresholds
To determine sex-specific thresholds (male vs. female) for the echocardiographic aortic valve calcium score (Echo-AVCS).
Time frame: 6 months
Correlation between the echocardiographic aortic valve calcium score and the calcium volume (mm³)
To assess the correlation between the echocardiographic aortic valve calcium score and the calcium volume (mm³) measured by cardiac computed tomography.
Time frame: 6 months
Correlation of the echocardiographic aortic valve calcium score and the presence and occurrence of patient symptoms
To correlate the echocardiographic aortic valve calcium score and the presence and occurrence of patient symptoms (angina, syncope, and dyspnea).
Time frame: 1-year
Association between the echocardiographic aortic valve calcium score and the time to aortic valve replacement (AVR)
To evaluate the association between the echocardiographic aortic valve calcium score and the time to aortic valve replacement (AVR) according to current ESC Guidelines.
Time frame: 1 year
Correlation of the echocardiographic aortic valve calcium score with the patient's NYHA Class.
To correlate the echocardiographic aortic valve calcium score with the patient's NYHA Class.
Time frame: 1 year
Correlation of the echocardiographic aortic valve calcium score with all-cause death at 1-year follow-up.
To correlate the echocardiographic aortic valve calcium score with all-cause death at 1-year follow-up.
Time frame: 1 year
Correlation of the echocardiographic aortic valve calcium score with cardiovascular death at 1-year follow-up.
To correlate the echocardiographic aortic valve calcium score with cardiovascular death at 1-year follow-up.
Time frame: 1 year
Correlation of the echocardiographic aortic valve calcium score with hospitalization for heart failure at 1-year follow-up.
To correlate the echocardiographic aortic valve calcium score with hospitalization for heart failure at 1-year follow-up.
Time frame: 1 year
Correlation of the echocardiographic aortic valve calcium score with major adverse cardiovascular events (cardiovascular death and hospitalization for heart failure) at 1-year follow-up.
To correlate the echocardiographic aortic valve calcium score with major adverse cardiovascular events (cardiovascular death and hospitalization for heart failure) at 1-year follow-up.
Time frame: 1 year
Not enrolling at this site.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.
Of 206 non-industry observational studies under Aortic Valve Stenosis, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 120. This study's planned 9 months is below that.
Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Azienda Ospedaliera "Sant'Andrea"